Encorafenib Alone or With Binimetinib Provides Long-Term Benefits in Melanoma
Source: Cancer Therapy Advisor, May 2024
Encorafenib, given with or without binimetinib, provides long-term benefits for patients with BRAF V600E/K-mutant advanced melanoma, according to results from the phase 3 COLUMBUS trial published in the European Journal of Cancer.
The COLUMBUS trial (ClinicalTrials.gov Identifier: NCT01909453) enrolled 577 patients with locally advanced unresectable or metastatic, BRAF V600E/K-mutant melanoma. The patients were randomly assigned to receive:
- Encorafenib at 450 mg once daily plus binimetinib at 45 mg twice daily (n=192)
- Encorafenib monotherapy at 300 mg daily (n=194)
- Vemurafenib monotherapy at 960 mg twice daily (n=191).